Literature DB >> 26663660

Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6-Selective Integrin Ligands.

Oleg V Maltsev1, Udaya Kiran Marelli1, Tobias G Kapp1, Francesco Saverio Di Leva2, Salvatore Di Maro3, Markus Nieberler4, Ute Reuning5, Markus Schwaiger6, Ettore Novellino2, Luciana Marinelli2, Horst Kessler7.   

Abstract

The αvβ6 integrin binds the RGD-containing peptide of the foot and mouth disease virus with high selectivity. In this study, the long binding helix of this ligand was downsized to an enzymatically stable cyclic peptide endowed with sub-nanomolar binding affinity toward the αvβ6 receptor and remarkable selectivity against other integrins. Computational studies were performed to disclose the molecular bases underlying the high binding affinity and receptor subtype selectivity of this peptide. Finally, the utility of the ligand for use in biomedical studies was also demonstrated here.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cyclic peptides; integrin inhibitors; molecular imaging; subtype selectivity; αvβ6 integrin

Mesh:

Substances:

Year:  2015        PMID: 26663660     DOI: 10.1002/anie.201508709

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  10 in total

1.  Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes.

Authors:  Giuseppe Floresta; Siham Memdouh; Truc Pham; Michelle T Ma; Philip J Blower; Robert C Hider; Vincenzo Abbate; Agostino Cilibrizzi
Journal:  Dalton Trans       Date:  2022-08-30       Impact factor: 4.569

2.  A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.

Authors:  Tobias G Kapp; Florian Rechenmacher; Stefanie Neubauer; Oleg V Maltsev; Elisabetta A Cavalcanti-Adam; Revital Zarka; Ute Reuning; Johannes Notni; Hans-Jürgen Wester; Carlos Mas-Moruno; Joachim Spatz; Benjamin Geiger; Horst Kessler
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

3.  Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions.

Authors:  Katja Steiger; Anna-Melissa Schlitter; Wilko Weichert; Irene Esposito; Hans-Jürgen Wester; Johannes Notni
Journal:  Mol Imaging       Date:  2017-01-01       Impact factor: 4.488

4.  Investigating the Interaction of Cyclic RGD Peptidomimetics with αVβ₆ Integrin by Biochemical and Molecular Docking Studies.

Authors:  Monica Civera; Daniela Arosio; Francesca Bonato; Leonardo Manzoni; Luca Pignataro; Simone Zanella; Cesare Gennari; Umberto Piarulli; Laura Belvisi
Journal:  Cancers (Basel)       Date:  2017-09-21       Impact factor: 6.639

5.  Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6.

Authors:  Stefanie Felicitas Färber; Alexander Wurzer; Florian Reichart; Roswitha Beck; Horst Kessler; Hans-Jürgen Wester; Johannes Notni
Journal:  ACS Omega       Date:  2018-02-28

Review 6.  Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy.

Authors:  Ping-Hsiu Wu; Abayomi Emmanuel Opadele; Yasuhito Onodera; Jin-Min Nam
Journal:  Cancers (Basel)       Date:  2019-11-13       Impact factor: 6.639

Review 7.  It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.

Authors:  Susanne Kossatz; Ambros Johannes Beer; Johannes Notni
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

Review 8.  Peptide therapeutics in the management of metastatic cancers.

Authors:  Debopriya Bose; Laboni Roy; Subhrangsu Chatterjee
Journal:  RSC Adv       Date:  2022-08-02       Impact factor: 4.036

Review 9.  Exploring the Role of RGD-Recognizing Integrins in Cancer.

Authors:  Markus Nieberler; Ute Reuning; Florian Reichart; Johannes Notni; Hans-Jürgen Wester; Markus Schwaiger; Michael Weinmüller; Andreas Räder; Katja Steiger; Horst Kessler
Journal:  Cancers (Basel)       Date:  2017-09-04       Impact factor: 6.639

10.  Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis.

Authors:  Xin Chang; Lei Xing; Yi Wang; Chen-Xi Yang; Yu-Jing He; Tian-Jiao Zhou; Xiang-Dong Gao; Ling Li; Hai-Ping Hao; Hu-Lin Jiang
Journal:  Sci Adv       Date:  2020-05-27       Impact factor: 14.136

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.